Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday?

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.

Benzinga

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Stocks Turn Mixed After an Early Rally

The S&P 500 Index ($SPX ) (SPY ) today is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.44%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September E-mini Nasdaq futures...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly will seek approval for experimental weight loss pill after promising study

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks.

Euronews

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Benzinga

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

The Independent UK

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly, ConocoPhillips And 3 Stocks To Watch Heading Into Thursday

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

Benzinga

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

Eli Lilly and Company (NYSE:LLY) will release earnings results for the second quarter before the opening bell on Thursday, Aug. 7.

Benzinga

Is Wall Street Bullish or Bearish on Eli Lilly Stock?

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in the company’s long-term growth prospects.

Barchart

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Benzinga

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

Barchart

Novo Nordisk Stock Sinks—But Is a Bottom Finally In?

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings

MarketBeat

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

Benzinga

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Benzinga

Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

Benzinga

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

Benzinga

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

Benzinga

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

MarketBeat

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

Barchart

Earnings Preview: What to Expect From Eli Lilly's Report

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

Benzinga

This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Says

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Rocket Lab Corporation (NASDAQ:RKLB) is a buy, adding that it is “one of the hottest stocks in the universe.”

Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.